12294-22-3

Basic information

• Product Name: mercaptoundecahydrododecaborate
• Synonyms: mercaptoundecahydrododecaborate;1,2,3,4,5,6,7,8,9,10,11-Undecahydro-12-mercapto dodecaborate(2-)
• CAS NO: 12294-22-3
• Molecular Formula: B12H12S
• Molecular Weight: 173.87
• Mol File: 12294-22-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: mercaptoundecahydrododecaborate(CAS DataBase Reference)
• NIST Chemistry Reference: mercaptoundecahydrododecaborate(12294-22-3)
• EPA Substance Registry System: mercaptoundecahydrododecaborate(12294-22-3)

Safety Data

• Hazardous Substances Data: 12294-22-3(Hazardous Substances Data)

Usage

General Description

Mercaptoundecahydrododecaborate, also known as BSH, is a boron-containing compound that has been studied for its potential use in boron neutron capture therapy (BNCT) for cancer treatment. mercaptoundecahydrododecaborate contains a boron-10 isotope, which has a high thermal neutron capture cross-section, making it an effective agent for selectively killing cancer cells when irradiated with thermal neutrons. BSH has been investigated for its ability to selectively accumulate in tumor cells and its favorable pharmacokinetic properties, making it a promising candidate for use in BNCT. Additionally, BSH has been shown to have low toxicity in normal tissues, further supporting its potential as a cancer treatment agent. Further research and clinical trials are ongoing to fully assess the safety and efficacy of BSH in BNCT.

InChI:InChI=1/B12/c1-2-3(1)5(1)6(1)4(1,2)8(2)7(2,3)9(3,5)11(5,6)10(4,6,8)12(7,8,9)11

Related news

The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (cas 12294-22-3) (BSH) fused cell-penetrating peptide08/16/2019

New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear reaction of boron-10 with neutron irradiation. The median survival of BNCT patients with glioblastoma was almost twice as long as those receiving standard therapy in a Japanese BNCT clinical trial. In this ...detailed

Intracellular targeting of sodium mercaptoundecahydrododecaborate (cas 12294-22-3) (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT)08/15/2019

The successful treatment of cancer by boron neutron-capture therapy (BNCT) requires the selective delivery of relatively high concentration of 10B compounds to malignant tumor tissue. This study focuses on a new tumor-targeting drug delivery system for BNCT that uses small (less than 200 nm in d...detailed

Liquid chromatographic determination of sodium mercaptoundecahydrododecaborate (cas 12294-22-3) in rat urine and plasma after precolumn derivatization08/14/2019

A high-performance liquid chromatographic (HPLC) method was developed for the determination of disodium mercaptoundecahydrododecaborate (BSH) in biological fluids. Monobromobimane was used as a precolumn derivatizing agent. A stable derivative was obtained. The derivative was separated on a C18 ...detailed

High-performance liquid chromatographic assay for sodium mercaptoundecahydrododecaborate (cas 12294-22-3) in rat tissues08/13/2019

Mercaptoundecahydrododecaborate (BSH) is an important agent for the boron neutron-capture therapy (BNCT). A sensitive high-performance liquid chromatographic (HPLC) method was developed for measuring BSH concentrations in rat tissues. Various tissue samples containing the drug were homogenized i...detailed

FT-IR measurement of mercaptoundecahydrododecaborate (cas 12294-22-3) in human plasma08/12/2019

A simple and rapid method for the quantitative measurement of mercaptoundecahydrododecarborate (BSH), (which presently is one of the most useful agents for Boron Neutron Capture Therapy) in human plasma was developed by using Fourier transform infrared spectroscopy. Different spacer thicknesses ...detailed

New functionalized mercaptoundecahydrododecaborate (cas 12294-22-3) derivatives for potential application in boron neutron capture therapy: Synthesis, characterization and dynamic visualization in cells08/11/2019

A series of mercaptoundecahydrododecaborate (B12H11SH2−, BSH) bearing mono- and dicarboxyalkyl derivatives was prepared, characterized, and their reactivity towards amidation and esterification in DMF was evaluated. Symmetrical alkylation of BSH was achieved by treatment with primary haloalkyl c...detailed

Quantitation of sodium mercaptoundecahydrododecaborate (cas 12294-22-3) by capillary isotachophoresis08/10/2019

A simple, specific and accurate method for the quantitation of sodium mercaptoundecahydrododecaborate, which is a very hygroscopic agent for boron neutron-capture therapy, was developed by using capillary isotachophoresis with sodium p-toluenesulphonate as an internal standard. Compound 1a was s...detailed

Interaction of mercaptoundecahydrododecaborate (cas 12294-22-3) (BSH) with phosphatidylcholine: relevance to boron neutron capture therapy08/09/2019

The interaction of mercaptoundecahydrododecaborate (B12H11SH2−, BSH) with phosphatidylcholine was investigated in this study in order to illuminate possible uptake mechanisms of BSH in tumor cells. BSH has been used clinically in Japan as a boron containing agent in patients with malignant brain...detailed